Skip to content
Firmagon(degarelix)
Firmagon (degarelix) is a protein pharmaceutical. Degarelix was first approved as Firmagon on 2008-12-24. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Firmagon
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Degarelix acetate
Tradename
Company
Number
Date
Products
FIRMAGONFerring PharmaceuticalsN-022201 RX2008-12-24
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
firmagonNew Drug Application2020-03-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Degarelix Acetate, Firmagon, Ferring
94150852032-04-27U-1895
106953982032-04-27U-1895
95793592029-02-10U-1978
107297392029-02-10U-1978
109738702029-02-10U-1978
ATC Codes
L: Antineoplastic and immunomodulating agents
— L02: Endocrine therapy antineoplastic and immunomodulating agents
— L02B: Hormone antagonists and related agents
— L02BX: Other hormone antagonists and related agents in atc
— L02BX02: Degarelix
HCPCS
Code
Description
J9155
Injection, degarelix, 1 mg
Clinical
Clinical Trials
118 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C6110452851594
Cardiovascular diseasesD002318EFO_0000319I98———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230173—111
Bone neoplasmsD001859EFO_0003820D16——1——1
InfertilityD007246EFO_0000545——1——1
Ovarian pregnancyD065172O00.2——1——1
Castration-resistant prostatic neoplasmsD064129——1——1
EndometriosisD004715EFO_0001065N80——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—2———2
Neoadjuvant therapyD020360—1———1
ProstatectomyD011468—1———1
Female infertilityD007247EFO_0008560N97—1———1
Ductal carcinoma breastD018270—1———1
Covid-19D000086382U07.1—1———1
LeukemiaD007938C95—1———1
Myelodysplastic syndromesD009190D46—1———1
Non-hodgkin lymphomaD008228C85.9—1———1
Multiple myelomaD009101C90.0—1———1
Show 2 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9————11
FertilityD005298————11
Urinary bladder neoplasmsD001749C67————11
Polycystic ovary syndromeD011085EFO_0000660E28.2————11
Fertilization in vitroD005307————11
Ovarian hyperstimulation syndromeD016471————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEGARELIX
INNdegarelix
Description
Degarelix is a polypeptide.
Classification
Protein
Drug classhormone-release inhibiting peptides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Identifiers
PDB—
CAS-ID214766-78-6
RxCUI475230
ChEMBL IDCHEMBL415606
ChEBI ID—
PubChem CID16136245
DrugBankDB06699
UNII IDSX0XJI3A11 (ChemIDplus, GSRS)
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
2798
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Q92644
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,065 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,177 adverse events reported
View more details